Bayesian Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Bayesian Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-9,400	Closed	-$229K	–	663
2024 Q2	$229K	Buy	+9,400	New	+$285K	0.03%	573
2023 Q2	–	Sell	-9,499	Closed	-$228K	–	782
2023 Q1	$228K	Buy	+9,499	New	+$170K	0.03%	580
2022 Q4	–	Sell	-11,399	Closed	-$169K	–	771
2022 Q3	$169K	Buy	+11,399	New	+$191K	0.03%	539
2022 Q2	–	Sell	-8,300	Closed	-$224K	–	775
2022 Q1	$224K	Buy	+8,300	New	+$212K	0.03%	619

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayesian Capital Management's ARCT Position: Q3 2024 in Review

Bayesian Capital Management sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 9,400 shares — an estimated $229K sold.

Bayesian Capital Management first reported a position in ARCT in Q1 2022 and held it in 4 quarters. The position peaked at $229K in Q2 2024. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

Bayesian Capital Management reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
Bayesian Capital Management sold 9,400 Arcturus Therapeutics shares in Q3 2024, an estimated $229K.
Bayesian Capital Management first reported a position in Arcturus Therapeutics in Q1 2022 and held it in 4 quarters.
Bayesian Capital Management's Arcturus Therapeutics position peaked at $229K in Q2 2024.
164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.